Document Detail

The lung resistance protein (LRP) predicts poor outcome in acute myeloid leukemia.
MedLine Citation:
PMID:  10500788     Owner:  NLM     Status:  MEDLINE    
To determine the clinical significance of the lung resistance protein (LRP) in acute myeloid leukemia (AML), we have studied LRP expression of leukemic blasts and its association with clinical outcome in patients with de novo AML. LRP expression of leukemic blasts was determined by immunocytochemistry by means of monoclonal antibody LRP-56. LRP expression at diagnosis was detected in 31 out of 86 (36%) patients and correlated with white blood cell count (p = 0.01). The complete remission rate of induction chemotherapy was 72% for all treated patients (n = 82). The complete remission rate was 81% for patients without LRP expression but only 55% for patients with LRP expression (p = 0.01). Overall survival and disease-free survival were estimated according to Kaplan-Meier in 82 and 59 patients, respectively. At a median follow-up of 16 months, median overall survival was 17 months for LRP-negative patients but only 8 months for LRP-positive patients (p = 0.006). Disease-free survival was 9 months for LRP-negative patients and 6 months for LRP-positive patients (p = 0.078). Thus LRP predicts for poor outcome indicating that the LRP gene is a clinically relevant drug resistance gene in AML.
R Pirker; G Pohl; T Stranzl; R W Suchomel; R J Scheper; U Jäger; K Geissler; K Lechner; M Filipits
Related Documents :
11113858 - Expression of cd44v6 but not e-cadherin or beta-catenin influences prognosis in primary...
11459088 - Prognostic value of vascular endothelial growth factor and its receptors flt-1 and flk-...
9474188 - Low p27 expression predicts poor disease-free survival in patients with prostate cancer.
16009948 - Detection of thymidylate synthase expression in lymph node metastases of colorectal can...
8394198 - A phase ii study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemothe...
12691318 - The role of neoadjuvant chemotherapy for squamous cell cervical cancer (ib-iiib): a lon...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Advances in experimental medicine and biology     Volume:  457     ISSN:  0065-2598     ISO Abbreviation:  Adv. Exp. Med. Biol.     Publication Date:  1999  
Date Detail:
Created Date:  1999-11-04     Completed Date:  1999-11-04     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0121103     Medline TA:  Adv Exp Med Biol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  133-9     Citation Subset:  IM    
Department of Internal Medicine I, University of Vienna Medical School, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antibodies, Monoclonal
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cytarabine / administration & dosage
Daunorubicin / administration & dosage
Disease-Free Survival
Drug Resistance, Multiple*
Etoposide / administration & dosage
Idarubicin / administration & dosage
Leukemia, Myeloid, Acute / blood,  drug therapy*,  mortality,  pathology
Middle Aged
Neoplasm Proteins*
Predictive Value of Tests
Survival Rate
Tretinoin / therapeutic use
Vault Ribonucleoprotein Particles*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/DAV regimen; 0/Neoplasm Proteins; 0/Vault Ribonucleoprotein Particles; 0/major vault protein; 147-94-4/Cytarabine; 20830-81-3/Daunorubicin; 302-79-4/Tretinoin; 33419-42-0/Etoposide; 58957-92-9/Idarubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Multidrug resistance related proteins in primary cutaneous lymphomas.
Next Document:  MRP expression in acute myeloid leukemia. An update.